Deliberate release into the
environment of GMOs for any other purposes than placing on the
market
Field trials with
herbicide tolerant soybeans - Bayer CropScience, S.L. - Spain |
Date of publication: May 17, 2004
Source:
http://gmoinfo.jrc.it/gmp_browse_geninf.asp
Notification
report
General information
Notification Number:
B/ES/04/10
Member State: Spain
Date of Acknowledgement: 17/03/2004
Title of the Project: Field trials with herbicide
tolerant soybeans.
Proposed period of release From:15/04/2004
To:30/11/2004
Name of the Institute(s) or Company(ies): Bayer
CropScience, S.L.;
3. Is the same GMPt release planned elsewhere in the
Community?
Not known
4 - Has the same GMPt been notified elsewhere by the same
notifier?
Yes
If yes, notification number(s):
-
Notified outside the Community
- USA: (APHIS 96-032-03N, 96-071-14N, 96-099-07N, 96-338-01N,
97-020-09N, 97-077-07N, 97-077-08N, 97-077-09N, 97-077-10N,
97-077-11N, 97-077-12N, 97-077-13N,97-080-06N, 97-098-02N,
97-098-05N, 97-111-05N y 97-120-01N) - Argentina: (CONABIA:
1996-1999) - Brazil: (CTNBIO: 2000) - Chile: (Department of
Agricultural Protection: 2000)
Genetically
modified plant
1. Complete name of the
recipient or parental plant(s)
|
Common Name |
Family Name |
Genus |
Species |
Subspecies |
Cultivar/breeding line |
| soybean
|
fabaceae
|
glycine
|
glycine
max |
|
A2704,
A5547 |
2. Description of the traits and characteristics which have
been introduced or modified, including marker genes and previous
modifications:
Glufosinate ammonium herbicide tolerance
Genetic
modification
3. Type of genetic
modification:
Insertion;
4. In case of insertion of genetic material, give the source
and intended function of each constituent fragment of the region
to be inserted:
Genetic elements which confer the phenotype of tolerance to
the herbicide glufosinate ammonium:
-P35S3 : Promotor region of the 35S transcript from Cauliflower
Mosaic Virus
-pat : Coding sequence of the phosphinothricin acetyltransferase
gene (pat) from Streptomyces viridochromogenes
-T35S3 : Terminator region of the 35S transcript from
Cauliflower Mosaic Virus
6. Brief description of the method used for the genetic
modification:
The transgenic soybean lines are generated using a particle
acceleration system
7. If the recipient or parental plant is a forest tree
species, describe ways and extent of dissemination and specific
factors affecting dissemination:
Not relevant.
Experimental
Release
1. Purpose of the release:
The purpose of this study is to generate reference material
from the Genetically Modified Organisms.
2. Geographical location of the site:
2004 : 1 location in Spain in the region of Aragón.
3. Size of the site (m2):
2004 : there will be a surface of approximately 700m˛ of for
each transgenic event.
4. Relevant data regarding previous releases carried out with
the same GM-plant, if any, specifically related to the potential
environmental and human health impacts from the release:
The previous releases took place in the US from 1996 to 1997.
A summary of the findings include:
- The genetic change is stable and the introduced gene produces
a protein which has a proven safety profile.
- The new glufosinate-tolerant soybean events share the
characteristics of soybean plants in agricultural production and
of soybean seed in commerce.
- In side-by-side comparisons with the non-transgenic parent
varieties of plant morphological characters and analysis of
components of nutritional importance, no evidence of pleiotropic
effects were detected.
- There is no cause for concern to non-target organisms
presented by the new plant varieties or the new use of the
herbicide, glufosinate.
- The potential for gene flow, the transfer of glufosinate
herbicide tolerance to wild or weedy soybean relatives, is
extremely low.
- The consequence of gene flow will not be detrimental to
current agronomic systems and can be managed by current
agricultural practices.
- There is no cause for concern for the human consumption and
for animal feed use of the seed or plant products derived from
the LibertyLink soybean varieties based upon transformation
events A2704-12 and A5547-127.
- Liberty system complements current soybean field weed control
practices.
- The agricultural requirements of soybean crops for human
intervention and temperate climate prevent glufosinate-tolerant
soybean from becoming invasive of new habitats as a result of
export activities.
Environmental
Impact and Risk Management
Summary of the potential
environmental impact from the release of the GMPts:
Genetically modified soybean has the same behaviour as
conventional soybean except for the characters encoded by the
inserted pat gene.
Due to flower development and the lack of wild relatives of
soybean in Europe, BCS consider that gene transfer is unlikely
to happen, neither to other species nor to conventional soybean.
However if a weed or a volunteer would receive the transgene,
this would not confer any selective advantage in the absence of
glufosinate treatment.
This transgenic soybean has been tested at various locations in
the US, Argentina, Brazil and in Chile and post-harvest
monitoring did not report any adverse effects on the
environment.
The pat gene has been approved in various crops since 1995, for
environmental release, food and feed by different agencies in
the world including Argentina, Australia, Canada, Europe, Japan
and the US. Regarding soybean specifically, transgenic lines
tolerant to herbicides are also developed and approved in
various countries since 1994.
Brief description of any measures taken for the management of
risks:
The trials will be conducted with an isolation distance of at
least 5 m from any other soybean.
The products harvested from the field trials will be used for
the production of reference material.
Each site will be visited on a regular basis during the trial
period.
Summary of foreseen field trial studies focused to gain new
data on environmental and human health impact from the release:
The planned field trials are designed in order to increase
seed for the production of reference material.
The planned field trials are not designed to address the impact
of the release on human health. |
|
|
|
